What's in Dr Madeleine Wilwerth's pipeline?

Dr Madeleine Wilwerth has 2 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Dr Madeleine Wilwerth's portfolio?

Top competitors by shared drug class: Charles University, Czech Republic, Fundación Pública Andaluza Progreso y Salud, Post Graduate Institute of Medical Education and Research, Chandigarh, University of Genova.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dr-madeleine-wilwerth.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Dr Madeleine Wilwerth — Portfolio Competitive Intelligence Brief

Dr Madeleine Wilwerth pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Levobupivacaine 0.07% + Sufentanil 0.3µg/ml	Levobupivacaine 0.07% + Sufentanil 0.3µg/ml	phase 3	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)	Anesthesia and Pain Management
Levobupivacaine 0.1% + Sufentanil 0.2µg/ml	Levobupivacaine 0.1% + Sufentanil 0.2µg/ml	phase 3	Local anesthetic + opioid combination	Voltage-gated sodium channels (levobupivacaine); mu opioid receptor (sufentanil)	Anesthesia / Pain Management

Therapeutic area mix

Anesthesia / Pain Management · 1
Anesthesia and Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Charles University, Czech Republic · 1 shared drug class
Fundación Pública Andaluza Progreso y Salud · 1 shared drug class
Post Graduate Institute of Medical Education and Research, Chandigarh · 1 shared drug class
University of Genova · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dr Madeleine Wilwerth:

Cite this brief

Drug Landscape (2026). Dr Madeleine Wilwerth — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dr-madeleine-wilwerth. Accessed 2026-05-16.